HER2-targeted Therapy: Routes of Administration

Video

Evaluating the benefits of the subQ vs IV formulation of the trastuzumab-pertuzumab combination for the management of HER2+ breast cancer and examining the potential use of at-home administration.

Evaluating the benefits of the subQ vs IV formulation of the trastuzumab-pertuzumab combination for the management of HER2+ breast cancer and examining the potential use of at-home administration.

Related Videos
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
© 2024 MJH Life Sciences

All rights reserved.